Literature DB >> 18161758

Immune activation and inflammation in HIV-1 infection: causes and consequences.

V Appay1, D Sauce.   

Abstract

Thorough research on HIV is progressively enabling us to understand the intricate mechanisms that link HIV-1 infection to the onset of immunodeficiency. The infection and depletion of CD4(+) T cells represent the most fundamental events in HIV-1 infection. However, in recent years, the role played by chronic immune activation and inflammation in HIV pathogenesis has become increasingly apparent: quite paradoxically, immune activation levels are directly associated with HIV-1 disease progression. In addition, HIV-1-infected patients present intriguing similarities with individuals of old age: their immune systems are characterized by a loss of regenerative capacity and an accumulation of ageing T cells. In this review, we discuss the potential reasons for the establishment of sustained immune activation and inflammation from the early stages of HIV-1 infection, as well as the long-term consequences of this process on the host immune system and health. A simplified model of HIV pathogenesis is proposed, which links together the three major facets of HIV-1 infection: the massive depletion of CD4(+) T cells, the paradoxical immune activation and the exhaustion of regenerative capacity. 2007 Pathological Society of Great Britain and Ireland

Entities:  

Mesh:

Year:  2008        PMID: 18161758     DOI: 10.1002/path.2276

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  308 in total

1.  Association of Markers of Inflammation with Sleep and Physical Activity Among People Living with HIV or AIDS.

Authors:  Michael D Wirth; Jason R Jaggers; Wesley D Dudgeon; James R Hébert; Shawn D Youngstedt; Steven N Blair; Gregory A Hand
Journal:  AIDS Behav       Date:  2015-06

2.  Early immune senescence in HIV disease.

Authors:  Seema Desai; Alan Landay
Journal:  Curr HIV/AIDS Rep       Date:  2010-02       Impact factor: 5.071

3.  Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy.

Authors:  Robert C Kalayjian; Rhoderick N Machekano; Nesrine Rizk; Gregory K Robbins; Rajesh T Gandhi; Benigno A Rodriguez; Richard B Pollard; Michael M Lederman; Alan Landay
Journal:  J Infect Dis       Date:  2010-06-15       Impact factor: 5.226

4.  IL-10 induces aberrant deletion of dendritic cells by natural killer cells in the context of HIV infection.

Authors:  Galit Alter; Daniel Kavanagh; Suzannah Rihn; Rutger Luteijn; David Brooks; Michael Oldstone; Jan van Lunzen; Marcus Altfeld
Journal:  J Clin Invest       Date:  2010-05-03       Impact factor: 14.808

Review 5.  Purinergic signaling and human immunodeficiency virus/acquired immune deficiency syndrome: From viral entry to therapy.

Authors:  Daniela F Passos; Maria Rosa C Schetinger; Daniela Br Leal
Journal:  World J Virol       Date:  2015-08-12

6.  Persistent immune activation in chronic HIV infection: do any interventions work?

Authors:  Reena Rajasuriar; Gabriela Khoury; Adeeba Kamarulzaman; Martyn A French; Paul U Cameron; Sharon R Lewin
Journal:  AIDS       Date:  2013-05-15       Impact factor: 4.177

7.  Fatigue-related gene networks identified in CD(14)+ cells isolated from HIV-infected patients: part I: research findings.

Authors:  Joachim G Voss; Adrian Dobra; Caryn Morse; Joseph A Kovacs; Robert L Danner; Peter J Munson; Carolea Logan; Zoila Rangel; Joseph W Adelsberger; Mary McLaughlin; Larry D Adams; Raghavan Raju; Marinos C Dalakas
Journal:  Biol Res Nurs       Date:  2013-01-16       Impact factor: 2.522

8.  Relationships between inflammation, immune activation, and bone health among HIV-infected adults on stable antiretroviral therapy.

Authors:  Kristine M Erlandson; Maryann OʼRiordan; Danielle Labbato; Grace A McComsey
Journal:  J Acquir Immune Defic Syndr       Date:  2014-03-01       Impact factor: 3.731

9.  Treating HIV-1 Infection: What Might the Future Hold?

Authors:  Mathias Lichterfeld; Kimon C Zachary
Journal:  Ther Adv Chronic Dis       Date:  2011-09       Impact factor: 5.091

10.  Persistent LCMV infection is controlled by blockade of type I interferon signaling.

Authors:  John R Teijaro; Cherie Ng; Andrew M Lee; Brian M Sullivan; Kathleen C F Sheehan; Megan Welch; Robert D Schreiber; Juan Carlos de la Torre; Michael B A Oldstone
Journal:  Science       Date:  2013-04-12       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.